康惠制药: 康惠制药关于股东减持股份计划公告

Summary of Key Points Core Viewpoint - The announcement details a share reduction plan by a major shareholder, Shanghai Sailoxian Enterprise Management Consulting Co., Ltd., which holds 4% of the total shares of Xi'an Kanghui Pharmaceutical Co., Ltd. The plan involves reducing up to 2,996,400 shares, representing 3% of the company's total shares, over a specified period. Group 1: Shareholder Information - The shareholder, Shanghai Sailoxian, holds 3,995,200 shares, accounting for 4% of the total share capital of the company [1][2] - The shares were acquired through an agreement transfer [2] Group 2: Reduction Plan Details - The reduction plan allows for a maximum of 2,996,400 shares to be sold, which is up to 3% of the total shares [1][2] - The reduction will occur through two methods: a maximum of 998,800 shares via centralized bidding and up to 1,997,600 shares through block trading [2] - The planned reduction period is from July 29, 2025, to October 26, 2025 [2] Group 3: Purpose and Conditions - The reason for the reduction is stated as necessary for the shareholder's own business development plans [2] - The implementation of the reduction plan is subject to market conditions and the company's stock price [2][3]